Robert Menendez actually said...

looking at the variety of factors to consider in terms of risk and underwriting is incredibly important as well

It is my understanding that negotiations on the pharmaceutical intellectual property text are still ongoing.

I compliment the Turks; I think they are doing an excellent job in managing a very difficult circumstance.

There was a frustration that the United States has not been decisive in providing direction.